Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Trial will be conducted by Angel Pharma and will study 12-week dosing of soquelitinib in patients with moderate-to-severe atopic dermatitis
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China.
Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater China and is responsible for all expenses related to its development in China.
“Atopic dermatitis affects patients worldwide, including a significant number in China where treatment with biologics and other systemic therapies is growing in use,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “Based on our clinical data to-date, we believe soquelitinib could be a compelling new treatment option for atopic dermatitis in China and globally, and we look forward to our partners at Angel Pharma exploring this potential. The Angel Phase 1b/2 trial will further expand the clinical experience with soquelitinib in atopic dermatitis, including a 12-week treatment period and a 400 mg once-daily dose. We anticipate they will begin enrolling patients in the third quarter 2025, with data from the Phase 1b portion available in 2026. In the U.S., we remain on track with the development of soquelitinib for atopic dermatitis with ongoing patient enrollment in our Phase 1 extension cohort and plans to initiate a Phase 2 trial by the end of year.”
Angel Pharma’s Phase 1b/2 clinical trial for soquelitinib in patients with atopic dermatitis will build on the data previously presented by Corvus from its ongoing Phase 1 trial by studying a longer treatment period and an additional dosing option.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?